Reviva Pharmaceuticals Hldg Inc (RVPH) Stock Price, Quote & News

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 501 8881

Fax: 408 904 6270

Website: www.revivapharma.com

Address:

10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States

Hashemehad Mar. 21 at 8:44 PM

$RVPH they had 8 consecutive trading days above a dollar since rs and then made the offering. Why the hell did they not wait 2 more days? That would have given them a chance to remain in nasdaq. Now they are 100 percent moving to otc. Are they that dumb or was that intentionally

0 · Reply

Vito99 Mar. 20 at 9:37 PM

$RVPH They ignored Seema https://www.sec.gov/Archives/edgar/data/1742927/000143774926009258/xslF345X06/rdgdoc.xml https://www.sec.gov/Archives/edgar/data/1742927/000143774926009260/xslF345X06/rdgdoc.xml

1 · Reply

DonkeyPuncherDude Mar. 20 at 7:48 PM

$RVPH I hope any penny flipper trying to swing trade this loses their ass.

0 · Reply

Spooot00 Mar. 20 at 11:29 AM

$RVPH for your situational awareness. If RVPH doesnt go above a dollar by the 27th ( next week ) it will be delisted

3 · Reply

Gropius Mar. 20 at 8:53 AM

$RVPH Yesterday, trading volume was 35 times the average! And profit-taking, as suggested here, can only account for a tiny fraction of the total! The new investor certainly didn't sell at a 40% loss! Either, curiously, dilution continued at this level, which would be a slap in the face to the new investor, or the cowards were liquidated. If further dilution is indeed taking place to generate 50 million, all options would be rendered invalid, and every purchase made yesterday would be pointless. This is going to be interesting!

0 · Reply

stazzy Mar. 20 at 6:40 AM

$RVPH glad all the uneducated pumpers on this garbage stock are getting what they deserve, hopefully you lose everything.

1 · Reply

SQUEAKSBANDIT Mar. 20 at 1:45 AM

$RVPH the warrant holders will short the common to hedge from now until the end of days 200% warrant coverage is just plain toxic

0 · Reply

DistributionEquity Mar. 20 at 12:42 AM

$RVPH tripled my position at 73 cents this morning. Thank you Mr market!!!!

1 · Reply

Pga27bam Mar. 19 at 10:55 PM

$RVPH will it be delisted ?

1 · Reply

Anomalies Mar. 19 at 10:22 PM

$RVPH 💊📉

0 · Reply

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Mar 18, 2026, 10:34 PM EDT - 2 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Mar 18, 2026, 4:10 PM EDT - 3 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Dec 29, 2025, 8:00 AM EST - 2 months ago

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Dec 23, 2025, 9:26 AM EST - 3 months ago

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Dec 23, 2025, 8:00 AM EST - 3 months ago

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Nov 13, 2025, 4:05 PM EST - 4 months ago

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 7, 2025, 4:08 PM EDT - 5 months ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Sep 19, 2025, 7:01 AM EDT - 6 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Sep 18, 2025, 9:26 PM EDT - 6 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Aug 14, 2025, 4:25 PM EDT - 7 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2025, 4:05 PM EDT - 11 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 30, 2025, 11:30 AM EDT - 1 year ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Feb 4, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering

Dec 11, 2024, 3:37 PM EST - 1 year ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

May 15, 2024, 8:00 AM EDT - 2 years ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 14, 2024, 8:00 AM EDT - 2 years ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 2 years ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present at the UBS Virtual CNS Day

Mar 7, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at the 36th Annual ROTH Conference

Feb 20, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Jan 25, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Hashemehad Mar. 21 at 8:44 PM

0 · Reply

Vito99 Mar. 20 at 9:37 PM

1 · Reply

DonkeyPuncherDude Mar. 20 at 7:48 PM

$RVPH I hope any penny flipper trying to swing trade this loses their ass.

0 · Reply

Spooot00 Mar. 20 at 11:29 AM

$RVPH for your situational awareness. If RVPH doesnt go above a dollar by the 27th ( next week ) it will be delisted

3 · Reply

Gropius Mar. 20 at 8:53 AM

0 · Reply

stazzy Mar. 20 at 6:40 AM

$RVPH glad all the uneducated pumpers on this garbage stock are getting what they deserve, hopefully you lose everything.

1 · Reply

SQUEAKSBANDIT Mar. 20 at 1:45 AM

$RVPH the warrant holders will short the common to hedge from now until the end of days 200% warrant coverage is just plain toxic

0 · Reply

DistributionEquity Mar. 20 at 12:42 AM

$RVPH tripled my position at 73 cents this morning. Thank you Mr market!!!!

1 · Reply

Pga27bam Mar. 19 at 10:55 PM

$RVPH will it be delisted ?

1 · Reply

Anomalies Mar. 19 at 10:22 PM

$RVPH 💊📉

0 · Reply

MickyD Mar. 19 at 10:22 PM

$RVPH 1 dollar plus tomorrow ?????

0 · Reply

biovaluable Mar. 19 at 10:09 PM

$RVPH sell

0 · Reply

biovaluable Mar. 19 at 9:20 PM

$RVPH chance to buying!

0 · Reply

MickyD Mar. 19 at 8:30 PM

$RVPH

1 · Reply

RobbyAxelrod1 Mar. 19 at 7:21 PM

$RVPH That offering is not big enough just do an atm be a lot easier.

0 · Reply

yellowdog11 Mar. 19 at 7:20 PM

$RVPH All I can say is good luck bhatt trying to sell those 1.5 shares and if you are going to try to dilute to raise 60 million plus good luck woof

1 · Reply

Whiskeyunderthebed Mar. 19 at 6:47 PM

$RVPH CECOT is waiting for your BHAT

0 · Reply

Golferhack12 Mar. 19 at 6:39 PM

$RVPH do not ever buy and hold the stock like this shame on you I bought a few thousand shares at 67 cents this morning and sold it at $85 I'm happy with that

0 · Reply

Tonyromo9 Mar. 19 at 6:28 PM

$RVPH shut down the company,and send the board to a prison in Siberia…straight abhorrent human trash

0 · Reply

Itsybitsybeanbag Mar. 19 at 6:17 PM

$RVPH BTW Brilla’s use patent expires in June 2028

0 · Reply

Itsybitsybeanbag Mar. 19 at 6:16 PM

$RVPH even if they close this offering these jackasses aren’t capable of running another trial they’ve known for two years that they needed to do this and decide to raise just now?? And waited for 18 months to meet with the FDA to get confirmation that they need a second phase 3. Bhat you are an embarrassment to your Amma.

0 · Reply

jag80 Mar. 19 at 6:01 PM

$RVPH Today is the 9th consecutive business day after RS to be compliant and stay above 1 dollar. If they fail to close above 1 dollar today, there is immediate delisting as the 10 consecutive day clock resets back to 0 and they have time only till March 27 to meet compliance.

2 · Reply

Market Cap	10.93M
Revenue (ttm)	0.00
Net Income (ttm)	-29.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,978,900
Avg Vol	419,095
Day's Range	N/A - N/A
Shares Out	5.84M
Stochastic %K	5%
Beta	0.10
Analysts	Strong Sell
Price Target	$30.00